Press Releases MediWound Ltd.

Equities

MDWD

IL0011316309

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
18.65 ^USD	-1.01%		+2.25%	+83.38%

03-21	MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	CI
03-21	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	04-25	GL
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	04-25	AQ
MediWound: Q4 Earnings Snapshot	03-21	AQ
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	03-21	GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	03-14	GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	03-14	AQ
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	02-12	GL
MediWound to Participate in Two Upcoming Investor Conferences	02-05	GL
MediWound to Participate in Two Upcoming Investor Conferences	02-05	AQ
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	01-09	GL
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	01-09	AQ
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army	12-29	AQ
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army	12-28	GL
MediWound Announces Peer-Reviewed Publication of EscharEx Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads	12-22	AQ
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads	12-21	GL
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	12-20	AQ
MediWound : Presentation – December 2023	12-18	PU
MediWound: Q3 Earnings Snapshot	11-21	AQ
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update	11-21	GL
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer	11-21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MediWound Ltd.

Equities

MDWD

IL0011316309

Press Releases

Filters